SCHEMBL1880475

SCHEMBL1880475

Cc1cccc2cc(C(C)O)c(Cl)nc12

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
PIK3CD O00329 1/20 0.43
KDR P35968 10/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 1/20 0.41
ATM Q13315 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NPC1 O15118 1/20 0.40
GAA P10253 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 1/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
MCL1 Q07820 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1886074 1.00 DRD4 (0.45) DRD4DRD3L3MBTL1PIK3CDKDR
SCHEMBL26529514 0.87 LMNA (0.47) DRD4DRD3L3MBTL1PIK3CDKDR
SCHEMBL4178743 0.85 PIK3CD (0.37) PIK3CDKDM4EATMKMT2AGAA
SCHEMBL4182711 0.85 PIK3CD (0.37) PIK3CDKDM4EATMKMT2AGAA
SCHEMBL3656008 0.84 DRD4 (0.45) DRD4DRD3L3MBTL1PIK3CDKDR
SCHEMBL717941 0.84 DRD4 (0.45) DRD4DRD3L3MBTL1PIK3CDKDR
SCHEMBL247015 0.83 PDE2A (0.34) PIK3CDMAPTKDM4EATMKMT2A
SCHEMBL4174119 0.83 PDE2A (0.34) PIK3CDMAPTKDM4EATMKMT2A
SCHEMBL844461 0.80 MAPT (0.46) DRD4DRD3L3MBTL1KDRMAPT
SCHEMBL20798376 0.79 KDM4E (0.38) L3MBTL1MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399483-B2 Quinoxaline and quinoline derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2013-03-19 US disclosed
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA, S.A. (BE) 2011-05-05 US disclosed
EP-2231641-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB Pharma, S.A. (BE) 2010-09-29 EP disclosed
WO-2009081105-A2 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-07-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105508-A1 QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS PDXK, PDPK1, PIKFYVE DRD4 3720/4885DRD3 2440/4885L3MBTL1 3240/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.